Rethinking the Approach to Nail Disorders
This Viewpoint discusses the need for a broader approach to nail pathology, in which infectious, inflammatory, systemic, and structural factors are considered. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders
This cross-sectional study examines the stigmatization of children and adolescents associated with the visibility and severity of chronic skin disorders. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
ALK -Positive Histiocytosis —A Distinct Histiocytic Entity Deserving Recognition—Reply
In Reply We read the Letter to the Editor by Kemps et al with interest. We believe that these cases belong to the spectrum of juvenile xanthogranuloma (JXG). Conventionally, JXG is divided into 3 clinical stages during the disease process (the early developed, xanthomatous, and regression stages) and 3 histopathological changes are observed accordingly (the early, classic, and transitional stages). In our previous study, approximately 34.8% of systemic JXG exhibited ALK-positive immunostaining and ALK translocation verified via ALK fluorescence in situ hybridization assays. Furthermore, 17.4% were BRAFV600E- variants. This...
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
ALK -Positive Histiocytosis —A Distinct Histiocytic Entity Deserving Recognition
To the Editor It is with great interest that we read the recent article by Xu et al that described 2 infants with systemic histiocytic neoplasms harboring ALK translocations who were successfully treated with the ALK inhibitor alectinib. To our surprise, the authors classified the disease as systemic juvenile xanthogranuloma (JXG) without any mention of ALK-positive histiocytosis and stated that the treatment method had not been previously reported. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Trichomegaly Due to Panitumumab
This case report describes an adult male patient with a severe acneiform eruption on his chest and back. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Rosacea Core Domain Set
This consensus statement uses the Delphi process to develop a core domain set for rosacea clinical trials and practice. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 24, 2024 Category: Dermatology Source Type: research
Laser and Light-Based Therapies for Hirsutism Management in Women With Polycystic Ovarian Syndrome
This Systematic Review synthesizes the existing literature regarding the effectiveness of laser and light hair reduction therapies, either as stand-alone treatments or in combination with systemic agents, in treating hirsutism for women with polycystic ovary syndrome. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Efficacy and Safety of Erenumab for Erythema and Flushing in Rosacea
This nonrandomized controlled trial analyzes the efficacy and safety of erenumab, an anti –calcitonin gene-related peptide receptor monoclonal antibody, for rosacea-associated erythema and flushing. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Weekly Laser Treatments for Port-Wine Birthmarks in Infants
This case series examines the improvement in port-wine birthmark clearance from before to after once-weekly pulsed dye laser therapy in patients younger than 6 months. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Treatment of Keratosis Lichenoides Chronica With Upadacitinib
This case report describes a 30-year-old man presenting with 1-year history of nonitchy red papules and patches who was subsequently treated with upadacitinib. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Hospitalization and Continuity of Care in Anti-MDA5 Dermatomyositis
This cohort study describes the clinical features, patient characteristics, and treatment of anti-melanoma differentiation –associated gene 5 (MDA5) dermatomyositis. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Calcitonin Gene-Related Peptide Inhibitors for Treatment of Rosacea
While many treatments are available for papules and pustules of rosacea, few are available for erythema and flushing. The 2019 Global Rosacea Consensus Panel recommends general skincare, β-blockers (eg, propranolol and carvedilol), and α-adrenergic agents (eg, brimonidine and oxymetazoline) for flushing and vascular lasers for persistent erythema. Because these treatments may not always be effective or tolerated, there remains an unmet need for additional options that can address symptoms of flushing and erythema in rosacea. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Error in Table
This article was corrected online. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Chronic Progressive Pink-Yellow Papules and Nodules
A 38-year-old man presented with numerous pink-yellow firm papules and nodules on the bilateral elbows for 10 years spreading to the hands and knees in the past year. What is your diagnosis? (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 17, 2024 Category: Dermatology Source Type: research
Onychomycosis
This Patient Page describes the risk factors, clinical features, diagnosis, and treatment of onychomycosis. (Source: JAMA Dermatology)
Source: JAMA Dermatology - April 10, 2024 Category: Dermatology Source Type: research
